Funding for this research was provided by:
National Institutes of Health (R01CA219836, R01CA242003, R21CA223371, R35CA239158, R01CA241191, R01CA211963)
Deutsche Forschungsgemeinschaft (KO 4627/2-1)
Leukemia and Lymphoma Society (#7011-16)
Received: 7 May 2020
Accepted: 29 June 2020
First Online: 16 July 2020
Ethics approval and consent to participate
: Animal experiments were approved by the Animal Care and Use Committee of University of Florida. There is no human subject participation.
: This study does not include any individual person’s data in any form.
: Y.H., S.K., X. Z, G.Z., and D.Z. are inventors of two pending patent applications for use of Bcl-xL PROTACs as senolytic and antitumor agents. G.Z. and D.Z. are co-founders of and have equity in Dialectic Therapeutics, which develops Bcl-xL PROTACs to treat cancer. D.M.W. received research support from AbbVie, Aileron, Daiichi Sankyo, Surface Oncology, and AstraZeneca and licensing fees from AstraZeneca and Aileron and is a paid consultant for AstraZeneca, EDO Biosciences, Myeloid Therapeutics, Bantam Therapeutics, and Travera. The remaining authors declare no competing financial interests.